全文获取类型
收费全文 | 2335篇 |
免费 | 137篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 115篇 |
妇产科学 | 36篇 |
基础医学 | 225篇 |
口腔科学 | 27篇 |
临床医学 | 199篇 |
内科学 | 507篇 |
皮肤病学 | 19篇 |
神经病学 | 295篇 |
特种医学 | 69篇 |
外科学 | 434篇 |
综合类 | 14篇 |
一般理论 | 1篇 |
预防医学 | 89篇 |
眼科学 | 97篇 |
药学 | 229篇 |
中国医学 | 1篇 |
肿瘤学 | 111篇 |
出版年
2024年 | 3篇 |
2023年 | 20篇 |
2022年 | 40篇 |
2021年 | 83篇 |
2020年 | 60篇 |
2019年 | 86篇 |
2018年 | 108篇 |
2017年 | 75篇 |
2016年 | 75篇 |
2015年 | 62篇 |
2014年 | 98篇 |
2013年 | 128篇 |
2012年 | 220篇 |
2011年 | 246篇 |
2010年 | 104篇 |
2009年 | 76篇 |
2008年 | 176篇 |
2007年 | 162篇 |
2006年 | 112篇 |
2005年 | 116篇 |
2004年 | 113篇 |
2003年 | 109篇 |
2002年 | 92篇 |
2001年 | 11篇 |
2000年 | 7篇 |
1999年 | 15篇 |
1998年 | 7篇 |
1997年 | 10篇 |
1996年 | 9篇 |
1995年 | 9篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 9篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 5篇 |
1985年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1978年 | 2篇 |
1976年 | 1篇 |
1959年 | 1篇 |
1925年 | 2篇 |
1924年 | 4篇 |
1908年 | 1篇 |
排序方式: 共有2488条查询结果,搜索用时 15 毫秒
31.
Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease 下载免费PDF全文
Zhihua Liu Robin K. Meray Tom N. Grammatopoulos Ross A. Fredenburg Mark R. Cookson Yichin Liu Todd Logan Peter T. Lansbury Jr. 《Proceedings of the National Academy of Sciences of the United States of America》2009,106(12):4635-4640
Ubiquitin C-terminal hydrolase-L1 (UCH-L1) is linked to Parkinson's disease (PD) and memory and is selectively expressed in neurons at high levels. Its expression pattern suggests a function distinct from that of its widely expressed homolog UCH-L3. We report here that, in contrast to UCH-L3, UCH-L1 exists in a membrane-associated form (UCH-L1M) in addition to the commonly studied soluble form. C-terminal farnesylation promotes the association of UCH-L1 with cellular membranes, including the endoplasmic reticulum. The amount of UCH-L1M in transfected cells is shown to correlate with the intracellular level of α-synuclein, a protein whose accumulation is associated with neurotoxicity and the development of PD. Reduction of UCH-L1M in cell culture models of α-synuclein toxicity by treatment with a farnesyltransferase inhibitor (FTI-277) reduces α-synuclein levels and increases cell viability. Proteasome function is not affected by UCH-L1M, suggesting that it may negatively regulate the lysosomal degradation of α-synuclein. Therefore, inhibition of UCH-L1 farnesylation may be a therapeutic strategy for slowing the progression of PD and related synucleinopathies. 相似文献
32.
33.
Dragana Nikolic Manfredi Rizzo Dimitri P Mikhailidis Norman C Wong Maciej Banach 《Expert opinion on investigational drugs》2015,24(10):1389-1398
Introduction: RVX-208 is a first-in-class, orally active, novel small molecule in development by Resverlogix Corporation (Calgary, AB, Canada). It acts through an epigenetic mechanism by inhibiting the bromodomain and extraterminal (BET) family of proteins, increasing apolipoprotein A-I (apoA-I) and targeting high-density lipoprotein (HDL) metabolism, including generating of nascent HDL and increased larger HDL particles, resulting in the stimulation of reverse cholesterol transport. RVX-208 also has a beneficial effect on inflammatory factors known to be involved in atherosclerosis and plaque stability. New therapeutic strategies are needed for patients with atherosclerosis.Areas covered: In this review, the authors evaluate the use of RVX-208 as an agent for the treatment of atherosclerosis. The article is based on a literature search considering both animal and human studies available on PubMed as well as Media Releases from the Resverlogix Corporation.Expert opinion: The current evidence suggests promising beneficial effects of this novel drug in the prevention and treatment of atherosclerosis and other metabolic disorders. Its unique mechanism of action is encouraging; it affects several pathways and has a modest effect on HDL levels. There is also a shift in particle size to larger HDL particles, which may have potent atheroprotective effects. Future clinical development is needed, including safety assessment. 相似文献
34.
Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies 总被引:1,自引:0,他引:1 下载免费PDF全文
35.
Eckart RE Love SS Atwood JE Arness MK Cassimatis DC Campbell CL Boyd SY Murphy JG Swerdlow DL Collins LC Riddle JR Tornberg DN Grabenstein JD Engler RJ;Department of Defense Smallpox Vaccination Clinical Evaluation Team 《Journal of the American College of Cardiology》2004,44(1):201-205
OBJECTIVES: The purpose of this study was to assess the follow-up of patients with vaccinia-associated myocarditis. BACKGROUND: With the threat of biological warfare, the U.S. Department of Defense resumed a program for widespread smallpox vaccinations on December 13, 2002. One-year afterwards, there has been a significant increase in the occurrence of myocarditis and pericarditis among those vaccinated. METHODS: Cases were identified through sentinel reporting to military headquarters, systematic surveillance, and spontaneous reports. RESULTS: A total of 540,824 military personnel were vaccinated with a New York City Board of Health strain of vaccinia from December 2002 through December 2003. Of these, 67 developed myopericarditis at 10.4 +/- 3.6 days after vaccination. The ST-segment elevation was noted in 57%, mean troponin on admission was 11.3+/- 22.7 ng/dl, and peak cardiac enzymes were noted within 8 h of presentation. On follow-up of 64 patients (96%) at a mean of 32 +/- 16 weeks, all patients had objective normalization of echocardiography, electrocardiography, laboratory testing, graded exercise testing, and functional status; 8 (13%) reported atypical, non-limiting persistent chest discomfort. CONCLUSIONS: Post-vaccinial myopericarditis should be considered in patients with chest pain within 30 days after smallpox vaccination. Normalization of echocardiography, electrocardiography, and treadmill testing is expected, and nearly all patients have resolution of chest pain on follow-up. 相似文献
36.
Emmanuel S Ganotakis Irene F Gazi John A Papadakis I Anita Jagroop Devaki R Nair Dimitri P Mikhailidis 《Clinical and applied thrombosis/hemostasis》2007,13(1):35-42
The correlation between 2 predictors of vascular events, plasma fibrinogen and serum lipoprotein (a), was evaluated in patients referred to a specialist clinic because of primary hyperlipidemia. A significant correlation existed between fibrinogen and lipoprotein (a) in nonsmokers but not in smokers. Plasma fibrinogen concentration correlated positively and significantly with serum lipoprotein (a) levels in men nonsmokers without cardiovascular disease and in women nonsmokers with cardiovascular disease. Nonsmoker women without cardiovascular disease had significantly higher plasma fibrinogen (3.63 g/L versus 3.07 g/L, P < .0001) than the corresponding men. Nonsmoker women with and without cardiovascular disease had significantly higher lipoprotein (a) levels than the corresponding groups of men (0.36 versus 0.18 g/L; P = .0015 and 0.40 versus 0.26 g/L; P = .008), respectively. The relationship between fibrinogen and lipoprotein (a) levels alters markedly depending on the population selected. This relationship is influenced by gender, the presence of cardiovascular disease and smoking status. 相似文献
37.
38.
W R Dimitri 《The Thoracic and cardiovascular surgeon》1985,33(1):61-62
Maneuvers to improve access during difficult mitral valve surgery such as excessive traction on the mitral annulus, retraction and inversion are attended with increased risk of serious complications. A needle holder has been designed to facilitate the placement of sutures during mitral valve or other intracardiac procedures where access is difficult. 相似文献
39.
Alexander Dimitri Miras Anna Kamocka Beln Prez-Pevida Sanjay Purkayastha Krishna Moorthy Ameet Patel Harvinder Chahal Gary Frost Paul Bassett Lidia Castagnetto-Gissey Lucy Coppin Nicola Jackson Anne Margot Umpleby Stephen Robert Bloom Tricia Tan Ahmed Rashid Ahmed Francesco Rubino 《Diabetes care》2021,44(5):1082
OBJECTIVERoux-en-Y gastric bypass (RYGB) characteristically enhances postprandial levels of glucagon-like peptide 1 (GLP-1), a mechanism that contributes to its profound glucose-lowering effects. This enhancement is thought to be triggered by bypass of food to the distal small intestine with higher densities of neuroendocrine L-cells. We hypothesized that if this is the predominant mechanism behind the enhanced secretion of GLP-1, a longer intestinal bypass would potentiate the postprandial peak in GLP-1, translating into higher insulin secretion and, thus, additional improvements in glucose tolerance. To investigate this, we conducted a mechanistic study comparing two variants of RYGB that differ in the length of intestinal bypass.RESEARCH DESIGN AND METHODSA total of 53 patients with type 2 diabetes (T2D) and obesity were randomized to either standard limb RYGB (50-cm biliopancreatic limb) or long limb RYGB (150-cm biliopancreatic limb). They underwent measurements of GLP-1 and insulin secretion following a mixed meal and insulin sensitivity using euglycemic hyperinsulinemic clamps at baseline and 2 weeks and at 20% weight loss after surgery.RESULTSBoth groups exhibited enhancement in postprandial GLP-1 secretion and improvements in glycemia compared with baseline. There were no significant differences in postprandial peak concentrations of GLP-1, time to peak, insulin secretion, and insulin sensitivity.CONCLUSIONSThe findings of this study demonstrate that lengthening of the intestinal bypass in RYGB does not affect GLP-1 secretion. Thus, the characteristic enhancement of GLP-1 response after RYGB might not depend on delivery of nutrients to more distal intestinal segments. 相似文献
40.